Destiny Pharma plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Destiny Pharma plc
What on earth would make a biotech company change the primary endpoint half way through a Phase III program and not discuss it with the FDA? There are at least two scenarios, neither of them good.
Destiny Pharma's XF-73 achieved an "exceptionally high" 99.5% reduction in Staphylococcus aureus bacterial nasal carriage in a mid-stage trial, a result that should attract a number of potential partners for the UK firm.
Public Company Edition: Three companies postponed or withdrew their offerings, but drug developers continue to pursue IPOs. Also, Biocon, BMS and Epizyme raised money through new debt, Five Prime capitalized on positive data and Synthetic Biologic engaged a strategic advisor.
Companies in talks with EU authorities for the supply of at least 200 million initial doses of their mRNA vaccine. Plus, other new partnerships around the world and an India pause for AstraZeneca's contender in line with global decision.